Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2005

View Archived Issues

In vivo studies demonstrate that PD-166326 may be effective in CML

Therapeutic potential of rh-bFGF in IBD

Merck & Co. reviews product and pipeline progress

Medarex cleared for phase I study of MDX-1100 for ulcerative colitis

Cytogen and Dow to develop PSMA antibody for cancer

Benitec identifies clinical candidate for HCV

Reata completes licensing agreement for anticancer compounds

SP-01A enters phase II study in treatment-experienced HIV patients

Approval for clinical studies with KB-2115

Antigen Express links up with Scripps to test modified DNA vaccine potency

GW and Bayer amend Sativex marketing agreement

Preliminary phase I results with PDE4 inhibitor IPL-455903

NSABP trial results required for Bonefos NDA approval

Phase II/III trial of CEP-1347 in Parkinson's disease discontinued

Shire plans four key regulatory submissions in 2005

JTP-27536: a novel therapy for allergic diseases

20-HETE synthesis inhibitor TS-011 beneficial in hemorrhagic and ischemic stroke

Functionality of TRPV1 receptors demonstrated in sebocytes with capsaicin

Recent patents impart therapeutic agents for neurological disorders

Antitumor effects found for phenoxodiol in advanced ovarian cancer

Reduced retinal vascular leakage found with ruboxistaurin in patients with DME

Update on the benefits of fluocinolone acetonide in posterior uveitis

Xibrom shows efficacy in reducing inflammation and pain after cataract surgery

New evidence supports the use of rebamipide for dry eye

Use of argatroban for heparin-induced thrombocytopenia claimed in GlaxoSmithKline patent

New analgesic agents revealed in patent literature

Mycamine gets U.S. launch

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....